YU46183B - PROCEDURE FOR OBTAINING PEPTIDES - Google Patents

PROCEDURE FOR OBTAINING PEPTIDES

Info

Publication number
YU46183B
YU46183B YU200586A YU200586A YU46183B YU 46183 B YU46183 B YU 46183B YU 200586 A YU200586 A YU 200586A YU 200586 A YU200586 A YU 200586A YU 46183 B YU46183 B YU 46183B
Authority
YU
Yugoslavia
Prior art keywords
carbon atoms
alkyl
formula
hydrogen
cycloalkylmethyl
Prior art date
Application number
YU200586A
Other languages
Serbo-Croatian (sh)
Other versions
YU200586A (en
Inventor
J.P. Rizza
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/900,934 external-priority patent/US4767743A/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU200586A publication Critical patent/YU200586A/en
Publication of YU46183B publication Critical patent/YU46183B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

cikloalkil sa 4 do 7 atoma ugljenika ili cikloalkilmetil sa 6 do 8 atoma ugljenika; R2 je vodonik ili alkil sa 1-3 atoma ugljenika; i R3 je hidroksi ili ostatak amino kiseline formule gde je X vodonik, alkil C1-C2 ili hidroksimetil i n je ceo broj od 0-4; i R4 i R5 su svaki nezavisno vodonik, alkil C1-C6, cikloalkilmetil sa 6 do 8 atoma ugljenika ili benzil, naznačen time, što se dehidrativno spaja jedinjenje formule gde su R1 i R2 kao što je prethodno definisano sa jedinjenjem formule u reakciono inertnom rastvoru, kao što je metilenhlorid, na 25-100 °C, gde funkcionalne grupe koje nisu obuhvaćene reakcijom mogu da se blokiraju i gde su X, n i R5 kao što je ranije definisano, posle čega se izvodi opciona faza selektivnog uklanjanja blokirajućih grupa i, po potrebi, dobijanje farmaceutski prihvatljivih baznih soli proizvoda. Postupak za dobijanje jedinjenja formule gde je R1 alkil sa 2 do 10 atoma ugljenik, sikloalkil sa 4 do 7 atoma ugljenika ili cikloalkilmetil sa 6 do 8 atoma ugljenika; R2 je vodonik ili alkil sa 1-3 atoma ugljenika; i R3 je hidroksi ili ostatak amino kiseline formule gde je X vodonik, alkil C1-C2 ili hidroksimetil i n je ceo broj od 0-4; i R4 i R5 su svako nezavisno vodonik, alkil C1-C6, cikloalkilmetil sa 6 do 8 atoma ugljenika ili benzil, naznačeno time, što se aciluje jedinjenje formule gde su R2 i R5 kao što je prethodno definisano, sa jedinjenjem formule R1CO-Hal u reakciono inertnom rastvoru, kao što je metilenhlorid, koji sadrži tercijalni amin, na 25° C, gde funkcionalne grupe koje nisu obuh-vaćene reakcijom mogu da se blokiraju i gde su R1 kao što je ranije definisano, Hal predstavlja halogen, posle čega se izvodi opciona faza selektivnog uklanjanja blokirajućih grupa i, po potrebi, dobijanje farmaceutski prihvatljivih baznih soli proizvoda. -Prijava sadrži još 2 zavisna zahteva.cycloalkyl of 4 to 7 carbon atoms or cycloalkylmethyl of 6 to 8 carbon atoms; R 2 is hydrogen or alkyl of 1-3 carbon atoms; and R3 is hydroxy or an amino acid residue of the formula where X is hydrogen, C1-C2 alkyl or hydroxymethyl and n is an integer from 0-4; and R 4 and R 5 are each independently hydrogen, C 1 -C 6 alkyl, cycloalkylmethyl having 6 to 8 carbon atoms, or benzyl, wherein a compound of the formula wherein R 1 and R 2 are as defined above is dehydratively coupled to a compound of the formula in a reaction inert solution , such as methylene chloride, at 25-100 °C, where unreacted functional groups can be blocked and where X, n and R 5 are as previously defined, followed by an optional step of selective removal of blocking groups and, by if necessary, obtaining pharmaceutically acceptable base salts of the product. Process for obtaining compounds of the formula where R1 is alkyl with 2 to 10 carbon atoms, cycloalkyl with 4 to 7 carbon atoms or cycloalkylmethyl with 6 to 8 carbon atoms; R 2 is hydrogen or alkyl of 1-3 carbon atoms; and R3 is hydroxy or an amino acid residue of the formula where X is hydrogen, C1-C2 alkyl or hydroxymethyl and n is an integer from 0-4; and R 4 and R 5 are each independently hydrogen, C 1 -C 6 alkyl, cycloalkylmethyl of 6 to 8 carbon atoms, or benzyl, indicated by acylating a compound of the formula wherein R 2 and R 5 are as defined above, with a compound of the formula R 1 CO-Hal in to a reactively inert solution, such as methylene chloride, containing a tertiary amine, at 25°C, where functional groups not involved in the reaction can be blocked and where R1 is as defined earlier, Hal represents halogen, after which optional step of selective removal of blocking groups and, if necessary, obtaining pharmaceutically acceptable base salts of the product. - The application contains 2 more dependent requests.

YU200586A 1985-11-25 1986-11-24 PROCEDURE FOR OBTAINING PEPTIDES YU46183B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8502351 1985-11-25
US06/900,934 US4767743A (en) 1986-08-27 1986-08-27 Peptide immunostimulants

Publications (2)

Publication Number Publication Date
YU200586A YU200586A (en) 1988-06-30
YU46183B true YU46183B (en) 1993-05-28

Family

ID=26772151

Family Applications (1)

Application Number Title Priority Date Filing Date
YU200586A YU46183B (en) 1985-11-25 1986-11-24 PROCEDURE FOR OBTAINING PEPTIDES

Country Status (12)

Country Link
KR (1) KR900004648B1 (en)
CN (1) CN1017436B (en)
AU (1) AU579501B2 (en)
CA (1) CA1295784C (en)
DK (1) DK170345B1 (en)
FI (1) FI86858C (en)
NO (1) NO170422C (en)
PH (1) PH22258A (en)
PL (2) PL150129B1 (en)
PT (1) PT83796B (en)
SU (1) SU1560058A3 (en)
YU (1) YU46183B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851388A (en) * 1986-01-23 1989-07-25 Pfizer Inc. Heptanoyl-glu-asp-ala-amino acid immunostimulants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565653A (en) * 1984-03-30 1986-01-21 Pfizer Inc. Acyltripeptide immunostimulants
WO1988001612A1 (en) * 1986-08-27 1988-03-10 Pfizer Inc. Processes and intermediates for n-(s-3-alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-d-alanine

Also Published As

Publication number Publication date
YU200586A (en) 1988-06-30
CN1017436B (en) 1992-07-15
CA1295784C (en) 1992-02-11
AU6561886A (en) 1987-05-28
FI864772A (en) 1987-05-26
FI864772A0 (en) 1986-11-24
PL268313A1 (en) 1988-07-07
DK561986D0 (en) 1986-11-24
KR870005012A (en) 1987-06-04
DK561986A (en) 1987-08-12
PL262563A1 (en) 1988-04-28
AU579501B2 (en) 1988-11-24
PL150055B1 (en) 1990-04-30
PT83796B (en) 1989-06-30
FI86858C (en) 1992-10-26
PH22258A (en) 1988-07-01
DK170345B1 (en) 1995-08-07
PL150129B1 (en) 1990-04-30
PT83796A (en) 1986-12-01
NO170422C (en) 1992-10-14
FI86858B (en) 1992-07-15
SU1560058A3 (en) 1990-04-23
KR900004648B1 (en) 1990-07-02
NO864689D0 (en) 1986-11-24
NO170422B (en) 1992-07-06
CN86107931A (en) 1987-07-01

Similar Documents

Publication Publication Date Title
ATE164575T1 (en) SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS
ATE215078T1 (en) IMPROVED METHOD FOR PRODUCING PROTECTED 3,4-DIHYDROXYBUTURIC ACID ESTERS
DE3363244D1 (en) Compounds, process for their preparation and their use as pharmaceutical preparations
ES8607287A1 (en) Novel 1,8-Naphthyridine derivatives, and process for preparation thereof.
ES2054826T3 (en) PEPTIDES WITH COLAGENASA INHIBITING ACTIVITY.
TW234116B (en) 2-Cyano-3-hydroxy-enamides and their preparation process
DK151627C (en) METHOD OF ANALOGUE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 4- (PHENYLALKENYL) IMIDAZOLD DERIVATIVES OR TOXIC PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS.
HUP9902576A1 (en) Novel erythromycin derivatives, method for preparing them, and use thereof as drugs
ES2000185A6 (en) Pyridonecarboxylic acid derivatives and process for their preparation.
MY100095A (en) 2-oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition.
MY103583A (en) Process for preparing substituted isoindolinone derivatives
ATE48001T1 (en) CEPHEM COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS.
ATE141606T1 (en) CEPHEM COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
HUP0203855A2 (en) Substituted piperazine derivatives as mtp inhibitors
DK0763024T3 (en) Process and intermediates for the preparation of piperazine derivatives
ES8308543A1 (en) Substituted 2-phenyl-2-(pyridyloxy)-ethyl amines and isosteric compounds, process for their preparation and use.
YU46183B (en) PROCEDURE FOR OBTAINING PEPTIDES
ATE148128T1 (en) ANTHRACYCLINGLYCOSIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DK623486A (en) GUANIDINOBENZOIC ACID ESTERATIVE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
GB1438931A (en) N-substituted 1,4-dihydropyridine compounds
CA2364199A1 (en) Novel bicyclic derivatives of aminopyrazinone, process for their preparation and pharmaceutical compositions containing them
ES8801637A1 (en) Derivatives of 2-fluoroalkylbenzimidazole, process for their preparation and pharmaceutical compositions containing them.
NO864665D0 (en) NEW BASIC SUBSTITUTED PYRIDINE COMPOUNDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICALS CONTAINING THEM, AND THEIR USE.
HRP20000027B1 (en) Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds
CA2093510A1 (en) Oxysulfonyl carbamates